These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20718249)

  • 1. Who, when, where, and how: salvage prostate cancer with radiotherapy.
    Chien CP; Roach M
    Oncology (Williston Park); 2010 Jul; 24(8):702, 704. PubMed ID: 20718249
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate cancer: non-metastatic.
    Wilt T
    Clin Evid; 2002 Jun; (7):812-23. PubMed ID: 12230707
    [No Abstract]   [Full Text] [Related]  

  • 3. Deciding which patients to treat with salvage radiotherapy after prostatectomy.
    Nguyen PL; D'Amico AV
    Oncology (Williston Park); 2010 Jul; 24(8):705, 711. PubMed ID: 20718250
    [No Abstract]   [Full Text] [Related]  

  • 4. [Salvage radiotherapy in rising PSA after radical prostatectomy].
    Carrie C; Pommier P
    Cancer Radiother; 2007 Nov; 11(6-7):370-2. PubMed ID: 17869564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer.
    Ost P; De Troyer B; Fonteyne V; Oosterlinck W; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1316-22. PubMed ID: 20675081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy.
    Gomez-Veiga F; Mariño A; Alvarez L; Rodriguez I; Fernandez C; Pertega S; Candal A
    BJU Int; 2012 Feb; 109 Suppl 1():17-21. PubMed ID: 22239225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.
    Choueiri TK; Chen MH; D'Amico AV; Sun L; Nguyen PL; Hayes JH; Robertson CN; Walther PJ; Polascik TJ; Albala DM; Moul JW
    Cancer; 2010 Apr; 116(8):1887-92. PubMed ID: 20162710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer (non-metastatic).
    Wilt T
    Clin Evid; 2003 Jun; (9):973-85. PubMed ID: 12967402
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option.
    Allen GW; Howard AR; Jarrard DF; Ritter MA
    Cancer; 2007 Oct; 110(7):1405-16. PubMed ID: 17685384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
    Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
    Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer.
    Krauss D; Kestin L; Ye H; Brabbins D; Ghilezan M; Gustafson G; Vicini F; Martinez A
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1064-71. PubMed ID: 20584576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
    Neulander EZ
    J Urol; 2004 Feb; 171(2 Pt 1):809; author reply 809-10. PubMed ID: 14713828
    [No Abstract]   [Full Text] [Related]  

  • 13. Salvage radiotherapy in patients with persisting/rising PSA after radical prostatectomy for prostate cancer.
    Bottke D; de Reijke TM; Bartkowiak D; Wiegel T
    Eur J Cancer; 2009 Sep; 45 Suppl 1():148-57. PubMed ID: 19775613
    [No Abstract]   [Full Text] [Related]  

  • 14. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?
    Miyamoto H; Messing EM; Chang C
    Nat Clin Pract Oncol; 2005 May; 2(5):236-7. PubMed ID: 16264955
    [No Abstract]   [Full Text] [Related]  

  • 15. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
    King CR; Presti JC; Brooks JD; Gill H; Spiotto MT
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technological advances in radiotherapy for the treatment of localised prostate cancer.
    Mangar SA; Huddart RA; Parker CC; Dearnaley DP; Khoo VS; Horwich A
    Eur J Cancer; 2005 Apr; 41(6):908-21. PubMed ID: 15808957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Is maximal androgenic blockade necessary in the treatment of prostatic cancer?].
    Matveev BP; Bukharkin BV
    Urologiia; 2003; (6):6-10. PubMed ID: 14708235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating prostate cancer, Part V: radiation therapy.
    Harv Mens Health Watch; 2008 Sep; 13(2):1-4. PubMed ID: 18822517
    [No Abstract]   [Full Text] [Related]  

  • 19. [Brachytherapy in the curative treatment of localized prostatic cancer].
    Flam T; Chauveinc L; Servois V; Rosenwald JC; Cosset JM; Thiounn N; Debré B
    Prog Urol; 2000 Feb; 10(1):3-13. PubMed ID: 10785912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does hormone therapy exacerbate the adverse effects of radiotherapy in men with prostate cancer? A quality of life study.
    Grant JD; Litwin MS; Kwan L; Lee SP; Steinberg ML; King CR
    J Urol; 2011 May; 185(5):1674-80. PubMed ID: 21419449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.